Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
As a traditional Chinese medicine compound, SaiLuoTong capsule is proven to have beneficial effects on learning and memory ability in animal models of vascular dementia (VaD). According to the result of the phase II study, the efficacy of SaiLuoTong capsule in the treatment of patients with VaD was better than that of placebo group and no difference in safety. So the study hypothesis is also that SaiLuoTong capsule will be effective in the treatment of patients with VaD and will be well tolerated. The purpose of the study is to confirm the efficacy and safety of SaiLuoTong capsule on patients with mild to moderate VaD. The outcome measures include general cognitive function, executive function, daily living skills, and mental behavior changes of symptoms in VaD patients.
Vascular dementia (VaD) is a clinical syndrome of acquired intellectual and functional impairment that results from cerebrovascular diseases. SaiLuoTong capsule is a traditional Chinese medicine compound; it is composed of ginseng extract (the main composition: ginseng total saponins), ginkgo biloba extract (the main composition: YinXingTong ester) and safflower extract (the main composition: the west safflower total glycosides). The function of SaiLuoTong capsule is Yiqi Huoxue and Huayu Tongluo in Chinese traditional medicine theory. Pharmacodynamics studies showed that SaiLuoTong capsule can significantly improve neurological symptoms caused by focal cerebral ischemia in animals, and learning and memory ability in animal models of VaD. The result of the phase II study showed that the efficacy of SaiLuoTong capsule in the treatment of patients with VaD was better than that of placebo group and no difference in safety. Based on these previous evidences, the investigators conduct this study to further confirm the efficacy and safety of SaiLuoTong capsule in patients with mild to moderate VaD. This study is a phase III clinical trial of SaiLuoTong capsule for treatment of vascular dementia. The study is a 52-week, multicentre, randomized, double -blind, placebo-controlled study.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| active group | Experimental | take two pills (120 mg) of SaiLuoTong capsule each time, twice a day, 0.5 hours before breakfast and dinner, taking with lukewarm water. |
|
| control group | Placebo Comparator | take two pills (120 mg) of placebo each time, twice a day, 0.5 hours before breakfast and dinner, taking with lukewarm water. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| SaiLuoTong capsule | Drug | 500 subjects are randomly divided into two groups by 3:1. 375 subjects in the active group take two pills(120mg) of SaiLuoTong capsule each time, twice a day, 0.5 hours before breakfast and dinner, taking with lukewarm water. |
| Measure | Description | Time Frame |
|---|---|---|
| Vascular Dementia Assessment Scale-cognitive Subscale(VaDAS-cog) | The VaDAS-cog comprises the Alzheimer's disease assessment scale(ADAS-cog) plus the Maze and Number Cancellation test to specifically assess executive function. The score of each item is summed to compute a total score. The range of the total score was from 0(no cognitive impairment) to 90(severe cognitive impairment). The data in the table below is the statistical data (mean,SD) of precise scores at screening and week 0 (baseline), while the statistical data of difference value compared to the score of Baseline at weeks 52. | Change from baseline VaDAS-cog score at Week 52 |
| Alzheimer's Disease Cooperative Study-clinical Global Impression of Change(ADCS-CGIC) | The Alzheimer's Disease Cooperative Study-clinical Global Impression of Change(ADCS-CGIC) involves comparison of data acquisition from both home and clinic and the use of both informant-ratings and self-ratings. Important outcomes include clinical global impressions of change (CGIC) as indicators of clinically meaningful change. In week 0 (baseline), the score was to judge the severity of the cognitive, 0(no evaluate),1(normal),2(slight intelligence obstacle),3(mide intelligence obstacle),4(moderate intelligence obstacle),5(significantly intelligence obstacle),6(severe intelligence obstacle),7(intelligent obstacle end-stage). In week 13,26,39,52, the score was to judge the change of the clinical global impression,1(improved significantly),2(improve),3(improve a little),4(no change),5(a little deteriorated),6(deteriorated),7(serious deterioration). | Change from baseline ADCS-CGIC score at Week 52 |
| Measure | Description | Time Frame |
|---|---|---|
| Alzheimer's Disease Cooperative Study-activities of Daily Living(ADCS-ADL) | To assess the daily living activity of the patients, including a subgroup in which there are 23 items to be checked and the total score is 78. A higher score represents a better daily living activity, vice versa. The score of each item is summed to compute a total score. The data in the table below is the statistical data (mean,SD) of precise scores at week 0 (baseline), while the statistical data of difference value compared to the score of baseline at weeks 26. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jianping Jia, Professor | Xuan Wu Hospital of Capital Medical University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Xuan Wu Hospital of Capital Medical University | Beijing | Beijing Municipality | 100053 | China | ||
| Peking University Shougang Hospital |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| placebo | Drug | 500 subjects are randomly divided into two groups by 3:1. 125 subjects in the control group take two pills(120mg) of placebo each time, twice a day, 0.5 hours before breakfast and dinner, taking with lukewarm water. |
|
| Change from baseline ADCS-ADL score at Week 26 |
| Alzheimer's Disease Cooperative Study-activities of Daily Living(ADCS-ADL) | To assess the daily living activity of the patients, including a subgroup in which there are 23 items to be checked and the total score is 78. A higher score represents a better daily living activity, vice versa. The score of each item is summed to compute a total score. The data in the table below is the statistical data (mean,SD) of precise scores at week 0 (baseline), while the statistical data of difference value compared to the score of baseline at weeks 52. | Change from baseline ADCS-ADL score at Week 52 |
| Mini-mental State Examination(MMSE) | The MMSE is a global test of cognitive function, for which the total score ranges from 0 to 30, with higher scores indicating lesser severity. The score of each item is summed to compute a total score. The data in the table below is the statistical data (mean, SD) of precise scores at screening (baseline), while the statistical data of difference value compared to the score of baseline at weeks 26. | Change from baseline MMSE score at Week 26 |
| Mini-mental State Examination(MMSE) | The MMSE is a global test of cognitive function, for which the total score ranges from 0 to 30, with higher scores indicating lesser severity. The score of each item is summed to compute a total score. The data in the table below is the statistical data (mean, SD) of precise scores at screening (baseline), while the statistical data of difference value compared to the score of baseline at weeks 52. | Change from baseline MMSE score at Week 52 |
| Clinical Dementia Rating(CDR Scale ) | The CDR is a numeric scale used to quantify the severity of symptoms of dementia (i.e. its 'stage'). Talk to the patients or those who know well about the patients and assess the 6 functions (memory, orientation, judgment and problem-solving ability, social activities, household duties and hobbies as well as self-care ability) to obtain the scores and based on the predetermined principles the CDR score is calculated. The diagnostic criteria[68]: normal-CDR=0; suspected dementia-CDR=0.5, mild dementia-CDR=1; moderate dementia- CDR=2; and serious dementia-CDR=3. The data in the table below is the statistical data (mean, SD) of precise scores at baseline and weeks 26. | Change from baseline CDR Scale score at Week 26 |
| Clinical Dementia Rating(CDR Scale ) | The CDR is a numeric scale used to quantify the severity of symptoms of dementia (i.e. its 'stage'). Talk to the patients or those who know well about the patients and assess the 6 functions (memory, orientation, judgment and problem-solving ability, social activities, household duties and hobbies as well as self-care ability) to obtain the scores and based on the predetermined principles the CDR score is calculated. The diagnostic criteria[68]: normal-CDR=0; suspected dementia-CDR=0.5, mild dementia-CDR=1; moderate dementia- CDR=2; and serious dementia-CDR=3. The data in the table below is the statistical data (mean, SD) of precise scores at baseline and weeks 52. | Change from baseline CDR Scale score at Week 52 |
| Clinical Dementia Rating sum of boxes(CDR-sb) | CDR-sb is the sum of boxes of CDR, with higher scores indicating severer degree of impairment. CDR-sb is the algebraic sum of 6 functional domains with a range of 0(normal) - 18(severe dementia). The data in the table below is the statistical data (mean,SD) of precise scores at weeks 0 (baseline), while the statistical data of difference value compared to the score of baseline at weeks 26. | Change from baseline CDR-sb score at Week 26 |
| Clinical Dementia Rating sum of boxes(CDR-sb) | CDR-sb is the sum of boxes of CDR, with higher scores indicating severer degree of impairment. CDR-sb is the algebraic sum of 6 functional domains with a range of 0(normal) - 18(severe dementia). The data in the table below is the statistical data (mean,SD) of precise scores at weeks 0 (baseline), while the statistical data of difference value compared to the score of baseline at weeks 52. | Change from baseline CDR-sb score at Week 52 |
| Blood biomarker: Brain-derived neurotrophic factor(BDNF) | The data in the table below is the statistical data (mean,SD) of precise measurement at weeks 0 (baseline), while the statistical data of difference value compared to the score of baseline at weeks 26. | Change from baseline BDNF at Week 26 |
| Blood biomarker: Brain-derived neurotrophic factor(BDNF) | The data in the table below is the statistical data (mean,SD) of precise measurement at weeks 0(baseline), while the statistical data of difference value compared to the score of baseline at weeks 52. | Change from baseline BDNF at Week 52 |
| Blood biomarker: Vascular endothelial growth factor(VEGF) | The data in the table below is the statistical data (mean,SD) of precise measurement at weeks 0 (baseline), while the statistical data of difference value compared to the score of baseline at weeks 26. | Change from baseline VEGF at Week 26 |
| Blood biomarker: Vascular endothelial growth factor(VEGF) | The data in the table below is the statistical data (mean,SD) of precise measurement at weeks 0 (baseline), while the statistical data of difference value compared to the score of baseline at weeks 52. | Change from baseline VEGF at Week 52 |
| Blood biomarker: Matrix metalloproteinase-9(MMP-9) | The data in the table below is the statistical data (mean,SD) of precise measurement at weeks 0 (baseline), while the statistical data of difference value compared to the score of baseline at weeks 26. | Change from baseline MMP-9 at Week 26 |
| Blood biomarker: Matrix metalloproteinase-9(MMP-9)) | The data in the table below is the statistical data (mean,SD) of precise measurement at weeks 0 (baseline), while the statistical data of difference value compared to the score of baseline at weeks 52. | Change from baseline MMP-9 at Week 52 |
| Blood biomarker: Interleukin-6(IL-6) | The data in the table below is the statistical data (mean,SD) of precise measurement at weeks 0 (baseline), while the statistical data of difference value compared to the score of baseline at weeks 26. | Change from baseline MMP-9 at Week 26 |
| Blood biomarker: Interleukin-6(IL-6) | The data in the table below is the statistical data (mean,SD) of precise measurement at weeks 0 (baseline), while the statistical data of difference value compared to the score of baseline at weeks 52. | Change from baseline MMP-9 at Week 52 |
| Vascular Dementia Assessment Scale-cognitive Subscale(VaDAS-cog) | The VaDAS-cog comprises the ADAS-cog plus the Maze and Number Cancellation test to specifically assess executive function. The score of each item is summed to compute a total score. The range of the total score was from 0(no cognitive impairment) to 90(severe cognitive impairment). The data in the table below is the statistical data (mean,SD) of precise scores at screening and week 0 (baseline), while the statistical data of difference value compared to the score of Baseline at weeks 13. | Change from baseline VaDAS-cog score at week 13 |
| Vascular Dementia Assessment Scale-cognitive Subscale(VaDAS-cog) | The VaDAS-cog comprises the ADAS-cog plus the Maze and Number Cancellation test to specifically assess executive function. The score of each item is summed to compute a total score. The range of the total score was from 0(no cognitive impairment) to 90(severe cognitive impairment). The data in the table below is the statistical data (mean,SD) of precise scores at screening and week 0 (baseline), while the statistical data of difference value compared to the score of Baseline at weeks 26. | Change from baseline VaDAS-cog score at week 26 |
| Vascular Dementia Assessment Scale-cognitive Subscale(VaDAS-cog) | The VaDAS-cog comprises the ADAS-cog plus the Maze and Number Cancellation test to specifically assess executive function. The score of each item is summed to compute a total score. The range of the total score was from 0(no cognitive impairment) to 90(severe cognitive impairment). The data in the table below is the statistical data (mean,SD) of precise scores at screening and week 0 (baseline), while the statistical data of difference value compared to the score of Baseline at weeks 39. | Change from baseline VaDAS-cog score at week 39 |
| Alzheimer's Disease Cooperative Study-clinical Global Impression of Change(ADCS-CGIC) | The ADCS-CGIC involves comparison of data acquisition from both home and clinic and the use of both informant-ratings and self-ratings. Important outcomes include clinical global impressions of change (CGIC) as indicators of clinically meaningful change. In week 0 (baseline), the score was to judge the severity of the cognitive, 0(no evaluate),1(normal),2(slight intelligence obstacle),3(mide intelligence obstacle),4(moderate intelligence obstacle),5(significantly intelligence obstacle),6(severe intelligence obstacle),7(intelligent obstacle end-stage). In week 13,26,39,52, the score was to judge the change of the clinical global impression,1(improved significantly),2(improve),3(improve a little),4(no change),5(a little deteriorated),6(deteriorated),7(serious deterioration). | Change from baseline ADCS-CGIC score at week 13 |
| Alzheimer's Disease Cooperative Study-clinical Global Impression of Change(ADCS-CGIC) | The ADCS-CGIC involves comparison of data acquisition from both home and clinic and the use of both informant-ratings and self-ratings. Important outcomes include clinical global impressions of change (CGIC) as indicators of clinically meaningful change. In week 0 (baseline), the score was to judge the severity of the cognitive, 0(no evaluate),1(normal),2(slight intelligence obstacle),3(mide intelligence obstacle),4(moderate intelligence obstacle),5(significantly intelligence obstacle),6(severe intelligence obstacle),7(intelligent obstacle end-stage). In week 13,26,39,52, the score was to judge the change of the clinical global impression,1(improved significantly),2(improve),3(improve a little),4(no change),5(a little deteriorated),6(deteriorated),7(serious deterioration). | Change from baseline ADCS-CGIC score at week 26 |
| Alzheimer's Disease Cooperative Study-clinical Global Impression of Change(ADCS-CGIC) | The ADCS-CGIC involves comparison of data acquisition from both home and clinic and the use of both informant-ratings and self-ratings. Important outcomes include clinical global impressions of change (CGIC) as indicators of clinically meaningful change. In week 0 (baseline), the score was to judge the severity of the cognitive, 0(no evaluate),1(normal),2(slight intelligence obstacle),3(mide intelligence obstacle),4(moderate intelligence obstacle),5(significantly intelligence obstacle),6(severe intelligence obstacle),7(intelligent obstacle end-stage). In week 13,26,39,52, the score was to judge the change of the clinical global impression,1(improved significantly),2(improve),3(improve a little),4(no change),5(a little deteriorated),6(deteriorated),7(serious deterioration). | Change from baseline ADCS-CGIC score at week 39 |
| Beijing |
| Beijing Municipality |
| 100144 |
| China |
| Xiyuan Hospital | Beijing | Beijing Municipality | China |
| Affiliated Hospital of Hebei University | Baoding | Hebei | China |
| Affiliated Hospital of Chengde Medical College | Chengde | Hebei | 067000 | China |
| Handan First Hospital | Handan | Hebei | 056000 | China |
| Hebei Central Hospital of petrochina | Langfang | Hebei | 065000 | China |
| The First Hospital of Hebei Medical University | Shijiazhuang | Hebei | 050000 | China |
| The Third Hospital of Hebei Medical University | Shijiazhuang | Hebei | 050051 | China |
| The Fourth Hospital of Medical University | Harbin | Hei Longjiang | China |
| The First People's Hospital of Luoyang | Luoyang | Henan | 471000 | China |
| The First affiliated Hospital of Nanyang Medical college | Nanyang | Henan | 473000 | China |
| Nanyang Second People's Hospital | Nanyang | Henan | 473003 | China |
| The First Hospital of Changsha | Changsha | Hunan | 41000 | China |
| Xiangya Boai Rehability Hospital | Changsha | Hunan | China |
| Yueyang Second People's Hospital | Yueyang | Hunan | 414000 | China |
| Baogang Hospital | Baotou | Inner Mongolia | 014000 | China |
| Inner Mongolia International Mongolian Hospital | Hohhot | Inner Mongolia | China |
| Taizhou Hospital of Chinese Medicine | Taizhou | Jiangsu | 225300 | China |
| Jiujiang University Clinical Medical College ▪ Jiujiang University Hospital | Jiujiang | Jiangxi | 332000 | China |
| Nanchang Hongdu Hospital of TCM | Nanchang | Jiangxi | China |
| Changzhi People's Hospital | Changzhi | Shanxi | 046000 | China |
| Jinzhong First People's Hospital | Jinzhong | Shanxi | China |
| Xianyang Hospital of Yan'an University | Xianyang | Shanxi | 712000 | China |
| Yuncheng Central Hospital | Yuncheng | Shanxi | China |
| The Second people's Hospital of Neijiang | Neijiang | Sichuan | China |
| Second Teaching Hospital of Tianjin University of Traditional Chinese Medicine | Tianjin | Tianjin Municipality | 300250 | China |
| The Second Hospital of Xingjiang Medical University | Ürümqi | Xingjiang | China |
| The Central Hospital of Lishui City | Lishui | Zhejiang | 323000 | China |
| ID | Term |
|---|---|
| D015140 | Dementia, Vascular |
| ID | Term |
|---|---|
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D002537 | Intracranial Arteriosclerosis |
| D020765 | Intracranial Arterial Diseases |
| D003704 | Dementia |
| D056784 | Leukoencephalopathies |
| D001161 | Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| C000603038 | sailuotong |
Not provided
Not provided
Not provided